Forest Celexa
Executive Summary
Labeling for citalopram oral solution cites rare postmarketing reports of weakness, hyperreflexia and incoordination following the use of a selective serotonin reuptake inhibitor and sumatriptan (Glaxo Wellcome's Imitrex). The 10 mg/5 mL oral formulation of Celexa was approved Dec. 22 for depression. The product is marketed in a tablet formulation by Forest and Warner-Lambert